Importance of TNF-related apoptosis-inducing ligand in pathogenesis of interstitial cystitis.
BACKGROUND
Although interstitial cystitis is an inflammatory disease, its etiopathogenesis is not clearly understood. The objective of the present study is to investigate the distribution of TNF-related apoptosis-inducing ligand (TRAIL) and its receptors in bladder biopsy samples of patients diagnosed with interstitial cystitis and the role of TRAIL in the pathogenesis of interstitial cystitis.


METHODS
TRAIL and its receptors were stained immunohistochemically in bladder biopsy samples of 27 patients diagnosed with interstitial cystitis, and the samples were evaluated independently by two pathologists and were scored in terms of expression intensity and distribution.


RESULTS
An evaluation of the results of the statistical analysis showed that the TRAIL-R4 receptor was immunohistochemically stained with a higher score than TRAIL-R1, TRAIL-R2, TRAIL-R3 receptors and TRAIL, with a statistically significant difference (P < 0.05).


CONCLUSIONS
These findings indicate that TRAIL-R4 is the predominant receptor in the interstitial cystitis inflammation.
Kutlu
Omer
O
Faculty of Medicine, Department of Urology, Akdeniz University, Antalya 07070, Turkey.
Akkaya
Erdem
E
Koksal
Ismail Turker
IT
Bassorgun
Ibrahim Cumhur
IC
Ciftcioglu
Mehmet Akif
MA
Sanlioglu
Salih
S
Kukul
Erdal
E
D001706:Biopsy; D018856:Cystitis, Interstitial / Q000209:etiology* / Q000473:pathology; D006801:Humans; D053220:Receptors, TNF-Related Apoptosis-Inducing Ligand / Q000032:analysis / Q000502:physiology; D053221:TNF-Related Apoptosis-Inducing Ligand / Q000032:analysis / Q000502:physiology*; D001743:Urinary Bladder / Q000737:chemistry / Q000473:pathology
D053220:Receptors, TNF-Related Apoptosis-Inducing Ligand; D053221:TNF-Related Apoptosis-Inducing Ligand
Urology. 2007 Apr;69(4 Suppl):24-33
17462476
J Exp Med. 1998 Dec 21;188(12):2375-80
9858524
J Urol. 2002 Jul;168(1):139-43
12050508
J Immunol. 2001 May 1;166(9):5337-45
11313369
Ann N Y Acad Sci. 1998 May 1;840:619-34
9629289
Semin Urol. 1991 May;9(2):74-87
1853017
Urol Res. 1990;18(4):263-6
2219589
J Urol. 1987 Oct;138(4):746-52
3477649
J Urol. 1982 Jan;127(1):152-4
6173491
J Immunol. 2006 Feb 15;176(4):2272-8
16455983
J Clin Invest. 1999 Jul;104(2):137-46
10411542
J Urol. 1999 Feb;161(2):553-7
9915447
Nat Immunol. 2003 Mar;4(3):255-60
12577054
J Urol. 1999 Feb;161(2):549-52
9915446
Neurourol Urodyn. 1994;13(5):515-20
7833969
Urology. 2002 Mar;59(3):329-33
11880064
J Immunol. 2000 Sep 1;165(5):2886-94
10946322
Lab Invest. 1985 Jul;53(1):1-4
4010226
Rheumatology (Oxford). 2007 May;46(5):783-9
17309888
J Urol. 2007 Jan;177(1):359-64
17162091
J Immunol. 2005 Apr 1;174(7):4025-33
15778360
Annu Rev Cell Biol. 1988;4:229-55
3143379
J Biol Chem. 1999 Oct 22;274(43):30603-10
10521444
Eur J Immunol. 2002 Aug;32(8):2246-54
12209637
Urol Int. 1985;40(4):211-6
3901473
Ann Chir Gynaecol Fenn. 1975;64(2):75-7
1137336
J Urol. 1991 Apr;145(4):732-5
2005689
Urology. 1997 May;49(5A Suppl):58-63
9146003
Hum Gene Ther. 2009 Oct;20(10):1177-89
19572802
Cancer Gene Ther. 2006 Jan 1;13(1):21-31
16052230
Cell Res. 2004 Oct;14(5):359-72
15538968
Br J Urol. 1983 Oct;55(5):488-92
6626894
Infect Immun. 1979 May;24(2):552-7
37168
Immunity. 1997 Dec;7(6):813-20
9430226
J Urol. 1998 Dec;160(6 Pt 1):2000-3
9817309
J Biol Chem. 2001 Apr 6;276(14):10767-74
11278284
J Urol. 2002 Jul;168(1):289-92
12050558
Urol Oncol. 2008 Mar-Apr;26(2):158-65
18312935
Cancer Res. 2004 May 15;64(10):3386-90
15150089
J Immunol. 2003 Jan 15;170(2):1027-33
12517970
J Membr Biol. 1976 Aug 27;28(1):1-40
9512
Immunity. 1995 Dec;3(6):673-82
8777713
J Urol. 2000 Mar;163(3):993-8
10688037
J Urol. 1995 Jul;154(1):6-15
7776457
Diabetes. 2003 Sep;52(9):2274-8
12941766